HIV-associated sensory neuropathy: still a problem in the post-stavudine era?

Catherine Cherry, Peter Kamerman, David LH Bennett, Andrew SC Rice

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Sensory neuropathy (SN) is a common and difficult to manage cause of chronic pain in HIV. Recent recommendations for earlier HIV treatment and avoidance of neurotoxic antiretroviral drugs (such as stavudine) have led to optimism that HIV-SN rates may decline. We present several reasons as to why HIV-SN is likely to remain prevalent, despite improvements in HIV management, together with clinical evidence confirming high HIV-SN rates in cohorts never exposed to neurotoxic medications. A combination of epidemiologic studies, laboratory work and clinical trials are needed to understand the problem of HIV-SN in the post-stavudine era. Improved HIV-SN prevention and management strategies are needed if the morbidity associated with HIV infection is to improve along with life expectancy.
Original languageEnglish
Pages (from-to)849 - 854
Number of pages6
JournalFuture Virology
Volume7
Issue number9
DOIs
Publication statusPublished - 2012

Cite this

Cherry, Catherine ; Kamerman, Peter ; Bennett, David LH ; Rice, Andrew SC. / HIV-associated sensory neuropathy: still a problem in the post-stavudine era?. In: Future Virology. 2012 ; Vol. 7, No. 9. pp. 849 - 854.
@article{6eed21a4a11d4d74a46a304482d65f43,
title = "HIV-associated sensory neuropathy: still a problem in the post-stavudine era?",
abstract = "Sensory neuropathy (SN) is a common and difficult to manage cause of chronic pain in HIV. Recent recommendations for earlier HIV treatment and avoidance of neurotoxic antiretroviral drugs (such as stavudine) have led to optimism that HIV-SN rates may decline. We present several reasons as to why HIV-SN is likely to remain prevalent, despite improvements in HIV management, together with clinical evidence confirming high HIV-SN rates in cohorts never exposed to neurotoxic medications. A combination of epidemiologic studies, laboratory work and clinical trials are needed to understand the problem of HIV-SN in the post-stavudine era. Improved HIV-SN prevention and management strategies are needed if the morbidity associated with HIV infection is to improve along with life expectancy.",
author = "Catherine Cherry and Peter Kamerman and Bennett, {David LH} and Rice, {Andrew SC}",
year = "2012",
doi = "10.2217/fvl.12.77",
language = "English",
volume = "7",
pages = "849 -- 854",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine",
number = "9",

}

HIV-associated sensory neuropathy: still a problem in the post-stavudine era? / Cherry, Catherine; Kamerman, Peter; Bennett, David LH; Rice, Andrew SC.

In: Future Virology, Vol. 7, No. 9, 2012, p. 849 - 854.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - HIV-associated sensory neuropathy: still a problem in the post-stavudine era?

AU - Cherry, Catherine

AU - Kamerman, Peter

AU - Bennett, David LH

AU - Rice, Andrew SC

PY - 2012

Y1 - 2012

N2 - Sensory neuropathy (SN) is a common and difficult to manage cause of chronic pain in HIV. Recent recommendations for earlier HIV treatment and avoidance of neurotoxic antiretroviral drugs (such as stavudine) have led to optimism that HIV-SN rates may decline. We present several reasons as to why HIV-SN is likely to remain prevalent, despite improvements in HIV management, together with clinical evidence confirming high HIV-SN rates in cohorts never exposed to neurotoxic medications. A combination of epidemiologic studies, laboratory work and clinical trials are needed to understand the problem of HIV-SN in the post-stavudine era. Improved HIV-SN prevention and management strategies are needed if the morbidity associated with HIV infection is to improve along with life expectancy.

AB - Sensory neuropathy (SN) is a common and difficult to manage cause of chronic pain in HIV. Recent recommendations for earlier HIV treatment and avoidance of neurotoxic antiretroviral drugs (such as stavudine) have led to optimism that HIV-SN rates may decline. We present several reasons as to why HIV-SN is likely to remain prevalent, despite improvements in HIV management, together with clinical evidence confirming high HIV-SN rates in cohorts never exposed to neurotoxic medications. A combination of epidemiologic studies, laboratory work and clinical trials are needed to understand the problem of HIV-SN in the post-stavudine era. Improved HIV-SN prevention and management strategies are needed if the morbidity associated with HIV infection is to improve along with life expectancy.

UR - http://www.futuremedicine.com/doi/abs/10.2217/fvl.12.77

U2 - 10.2217/fvl.12.77

DO - 10.2217/fvl.12.77

M3 - Article

VL - 7

SP - 849

EP - 854

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 9

ER -